Paying for Innovation: First-in-Class vs. Advance-in-Class drugs
Tuesday 13th May 2025 13:00 - 14:00 (BST)
In conjunction with the London School of Economics (LSE): How decision-makers perceive different types of pharmaceutical innovation
Masterclass Details:
Pharmaceutical innovation is critical to advancing healthcare, but how do decision-makers differentiate between ground-breaking and incremental advancements?
In this 60-minute masterclass for LSAA members, London School of Economics (LSE) Professor Panos Kanavos, PhD, will explore how Health Technology Assessment (HTA) agencies assess and reimburse First-in-Class (FIC) and Advance-in-Class (AIC) drugs across six global markets: England, Scotland, France, Germany, Australia, and Canada.
This masterclass will explore the challenges FIC drugs face, from longer HTA timelines to higher rejection rates, and compare them with AIC and Addition-to-Class (AdTC) drugs.
Gain insights into how regulatory approval pathways, clinical trial evidence, and decision-modifying factors influence HTA outcomes and market access.
Join us live with LSE Professor Kanavos to deepen your understanding of how HTA agencies assess value.
Key Learning Objectives:
- Time-to-HTA decision and access: FIC drugs take 40% longer on average to reach patients compared with AIC drugs
- HTA outcomes: FIC drugs are twice as likely to be rejected by HTA agencies compared with AIC and AdTC drugs
- Regulatory approval: 40% of FIC drugs were approved via accelerated pathways compared to 19% of AIC and AdTC drugs, impacting value assessment
- Clinical evidence: Only 35% of FICs had an active comparator in trials, compared to 53% of AICs, influencing HTA decisions
- Pay-for-innovation: Additional clinical benefit, rather than a novel mechanism of action, is the key determinant in HTA approvals
Can’t make the date? Register and we’ll send you a link to the recording so you can watch it on demand in your own time.
-
Date and time
13th May 2025 13:00 – 14:00 (BST)
